Company intelligence / Profile preview

Opus Biosciences

Berkeley, California, United Statesopusbiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Opus Biosciences is developing a next-generation lipid nanoparticle platform for safer, more effective, and cost-efficient delivery of genetic medicines. The technology aims to overcome current LNP limitations such as toxicity, immunogenicity, payload constraints, and re-dosing challenges. No clinical results have been published yet; the company is focused on preclinical development and technology validation[1][3][6].

Therapeutic areas: Other
Modalities: mRNA therapeuticsGenetic medicines (via lipid nanoparticle delivery)
Industry: Drug Discovery Services

Partnerships

No major pharmaceutical or biotech partnerships publicly announced as of May 2025.

Beyond the preview

Go deeper on Opus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opus Biosciences.

Explore the full profile